You just read:

Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy

News provided by

Mallinckrodt plc

Dec 11, 2017, 09:16 ET